Topotecan-pazopanib combination therapy for aggressive pediatric solid tumors
Posted in the Pediatric Cancer Forum
#1 Jul 27, 2011
A recent study reported in the journal Clinical Cancer Research, metronomic administration of Topotecan and pazopanib showed a statistically significant antitumor activity compared to respective single agents in pediatric tumor mouse models and represent a valid option as a maintenance therapy in aggressive pediatric solid tumors. In vitro, Topotecan caused a dose-dependent decrease in viabilities of all cell lines, while pazopanib did not. In vivo, combination of Topotecan + Pazopanib (TP+PZ) demonstrated significant anti-tumor activity and significant enhancement in survival compared to the respective single agents in all models. Pharmacokinetic studies of both drugs did not reveal any drug-drug interaction. News link: http://www.sciclips.com/sciclips/drug-discove...
Add your comments below
|Genetic hallmarks of acute lymphoblastic leukem...||Oct '16||Stephany McDowell||1|
|Retired Ringling Bros. circus elephants have a ...||Sep '16||Stephany McDowell||1|
|levitra forums, levitra coupons & levitra adver... (Apr '16)||Apr '16||Hopkins||1|
|doctors urge halt on viagra production (Mar '16)||Mar '16||Douglas||1|
|Save the Chickens and the Children (Aug '15)||Aug '15||Gof print||1|
|Trusted Translations Launches 'Translation for ... (Jun '09)||Jun '15||Caroline||3|
|Will new FDA pediatric cancer drug save lives? (May '15)||May '15||jordennancy23||1|
Find what you want!
Search Pediatric Cancer Forum Now
Copyright © 2016 Topix LLC